Ligand And Organon Terminate Avinza Co-Promotion Agreement
This article was originally published in The Pink Sheet Daily
Return of rights for the extended-release morphine to Ligand will not be complete until end of transitional period in September.
You may also be interested in...
Payment includes possible royalties from alternate formulations of the extended-release morphine product developed through a King/Elan partnership.
Health plans should account for the rise in utilization that occurs with use of mail-order pharmacy when deciding if mail order saves money, Ohio Public Employees Retirement System Director of Healthcare Scott Streator said at the recent Academy of Managed Care Pharmacy Educational Conference in Chicago